<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129602">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02126176</url>
  </required_header>
  <id_info>
    <org_study_id>PUNHDM-adherence</org_study_id>
    <nct_id>NCT02126176</nct_id>
  </id_info>
  <brief_title>Protopic Adherence and Efficacy in Korean Eczema Patient</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pusan National University Hospital</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the dosage of 0.1% tacrolimus ointment
      applied on unit area of eczema influence the efficacy of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <target_duration>2 Weeks</target_duration>
  <primary_outcome>
    <measure>clinical assessments of erythema, scaling, and pruritus</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>EASI score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical assessments of erythema, scaling, and pruritus</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>TIS score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical assessments of erythema, scaling, and pruritus</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>IGA/PGA score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical assessments of erythema, scaling, and pruritus</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>DLQI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical assessments of erythema, scaling, and pruritus</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>itching VAS scale</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Atopic Dermatitis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patient with atopic dermatitis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  at least 19 years of age with a diagnosis of atopic dermatitis

          -  treated with protopic 0.1% ointment

        Exclusion Criteria:

          -  treated with other medication or topical agent

          -  skin lesion on the scalp or hand and foot

          -  pregnant women/lactating women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Byung-Soo Kim, Ph.D.</last_name>
    <phone>82-51-240-7338</phone>
    <email>dockbs@pusan.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of dermatology, Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 27, 2014</lastchanged_date>
  <firstreceived_date>April 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
